Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign
Executive Summary
New GDUFA program fee is high enough that sponsors may withdraw applications to reduce their fee exposure, agency estimates.
You may also be interested in...
FDA's Generic Approvals Catch A Bit Of Breath In July But Continue At Fast Pace
US Generic drug approvals drop in July, but still are above the monthly average for the year, potentially signaling a new expected output.
FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit
Prioritizing ANDAs entering markets with fewer than three approved generics not expected to become a major advantage until first-cycle clearances increase.
Generic Industry Consolidating But Still Mysterious
Nearly 2,000 ANDAs remain unclaimed as US FDA begins fee calculations for GDUFA II.